Follow us

Open Orphan (ORPH)

Open Orphan (ORPH) at ShareSoc September 2019

16 September 2019

Presentation by Cathal Friel, Co-Founder

ORPH came out of a reverse takeover of Venn Life Sciences earlier this year. Cathal Friel outlines what they’re up to, and their vision.

Introduction – 00:18
A pharma services company – 02:02
The founders – 03:14
The orphan drug sector – 06:48
Combining high-margin pharma with digital & data offerings – 10:35
Founders investment – 12:15
Transforming Venn Life Sciences – 13:04
Targetting to add Eu30m in high margin revenues by 2022 – 15:45
Virtual Rep & Access platform – 18:45
Open Orphan’s Geonomic Health Data Platform – 23:03
Summary – 28:15
Q&A – 30:45

Open Orphan plc, formerly Venn Life Sciences Holdings plc, is engaged in the pharma services business. The Company is also engaged in building an orphan drug consulting services platform that helps pharma companies commercialize their products in Europe. The Company consists of four elements: a European clinical research organization and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians, and a Health Data Platform. The Company provides fragmented orphan drug services. The Company acquires and consolidates series of orphan drug services companies. It also provides digital data platforms to support companies in research & development and commercialization.

Listen on the go


PIWORLD provides investors with the latest news and insight about listed companies and their management through either live or recorded investor presentations, management interviews, Capital Market Days and corporate overviews, together with interviews with leading fund managers or esteemed private investors in the small cap world.

Our Services

PIWORLD delivers high quality audio and video content to present anything from full-year & interim results to Capital Markets Days and corporate overviews. We bridge the gap between listed companies and the private investor community, who drive the share price and provide liquidity, providing a time and cost effective medium to reach this diverse and important audience.